Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
when your goal is spelled out, there is only one hope/possibility; when you hide your goal (legally of course despite much grudge received), the possibilities are numerous!
In a shark infested waters, our journey will be clear and smooth with that kind of strategy.
If you still don't get it, better invest in other stocks where every moves will be broadcasted.
But, expect our strategy changes into the open, when we successfully accomplish our first journey.
I am willing to inject a little bit of fuel into our journey every now and then.
https://clincancerres.aacrjournals.org/content/27/1/11
CCR Perspectives in Regulatory Science and Policy
U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program
R. Angelo de Claro, Jennifer J. Gao, Tamy Kim, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver and Richard Pazdur
Add to Cart ($50)
DOI: 10.1158/1078-0432.CCR-20-2220 Published January 2021
Abstract
The FDA Oncology Center of Excellence commenced the Real-Time Oncology Review (RTOR) pilot project in February 2018 to facilitate earlier submission of topline results and datasets to support an earlier start to the FDA application review. RTOR was initially begun to support supplemental drug applications to add new indications, dosing regimens, or other clinical information to the prescribing information, but was later expanded to include original new drug applications and biological license applications for new molecular entities (NME). From February 2018 to April 2020, RTOR was used to support the submission and review of drug approvals for 20 oncology applications (11 for solid tumor and nine for hematologic malignancy indications). Two were NME drug approvals and 18 were supplemental approvals. All of the applications received priority review and nine (45%) applications had received breakthrough therapy designation status. FDA received the RTOR submissions a median of 5.7 weeks (range 1.7–16.2 weeks) prior to the full application submission. The median time from application submission to FDA approval was 3.3 months (range 0.4–5.9 months). RTOR was also integrated with other review programs including the Assessment Aid and Project Orbis programs. Innovative regulatory processes are critical to expedite the rigorous review of impactful products across the FDA.
Footnotes
Clin Cancer Res 2021;27:11–4
Received June 9, 2020.
Revision received July 20, 2020.
Accepted August 17, 2020.
Published first August 19, 2020.
©2020 American Association for Cancer Research.
This last post of mine for today is dedicated to the memory of those who have sold today after NWBIO secured about $11 million non-diluted loan four months after data lock on 5 October;
of those who had sold when blinded blended paper was published a few years ago, and subsequent uptrend OS data revealed; and
of those who had sold after German and UK revealed on their respective clinical trial registries the up-to-date revised, reordered endpoints.
What a short-sight, and what a pity!
of those who have dared or joyfully bought on those above events.
God blesses patients!
Exactly timung. Anyone at this point is still thinking we are waiting for a simple TLD is poor in normal brain function.
Yes TLD is pending, yes it will come out.
But, what we are actually waiting at this point is not a simple TLD and/or publication.
Don't need me to specify, and use your own brain function correctly ladies and gentlemen.
In other words, instead of waiting for a price hike one day to $3, we are waiting for a one day rocket up to $6.
Exactly, no sane person/entity would sign that kind of loan deal with a company whose pivotal phase 3 trial data was locked more than 4 long months ago without signing a NDA.
Yes one more evidence the trial is a success (I don't need this evidence anyhow as my previous multiple posts have revealed my confidence 100% based on data we have known so far about this trial and other failed trials as well as how SOC has panned out over decades)
The point as always is how successful the trial will be.
I think as least we will have 4 RA approval of DCVax-L for both nGBM and rGBM.
My last order for today as of now at 9:51am is much higher than yours at the current price of $1.33.
I will see what happen and may adjust my order if not filled.
Good luck
See you all tomorrow.
Bought 20k just now, and it's just starting for today.
At this price, even the weakest of Island boys would not convert any warrants or short any shares against their warrants. It's no action for them.
So the pathetic MMs or those funds who want to start a position or add more are playing with pathetic retail for a few share they can chip off.
In this sense, those MMs such as cdel and jane are just as pathetic as the pathetic retails.
Instead, to remove the pathetic hats from these MMs and funds's bald heads, they should stop acting now and the price will naturally appreciate.
Trust me, if price is a few dimes higher, they can get more shares in their coffers because there are more pathetic retail and island boys selling at "high" price than "low" price.
Men, I don't know why I am writing this since my buy orders have not been filled completely yet.
Hello $1.35 today, hello $10, $30... tomorrow (not literally of course)
Nothing in between but accumulation as many as you can afford. Please don't eat ramen noodles!
Primary endpoint will be readily met statistically significantly, so will at least some secondary endpoints if not all.
DCVax-L for GBM alone would grantee a share price in the range from $10-$30.
And it's just a fraction of the platform technology DCVax consisting of DCVax-L for all solid operable tumors and DCVax-D for all solid inoperable tumors.
Use a calculator and your brain to calculate whatever way you like, the numbers of potential share price is staggering, any numbers from $30 up is achievable.
Based on what we all know, DCVax-L trial for GBM is a success, which validates the MOA or the concept of DCVax platform.
All others are just FUDs.
Investing in accordance with your own DD man.
[btw, to be fair I need to talk about my investment: I have been net net increasing my investment and planned to do so until at least after the release of data, either tld, or more detail analysis. No time to constantly tear down anything speculative. Simply no time and not wise at the darkest time before dawn]
Exactly troc. It's one more sign built upon the general understanding or good practice that if the trial failed (I would deem a trial fails if it failed to meet its primary endpoint even later the underlying treatment could be approved from other strong indication), the company should have notified the general public.
Of course the blended blinded data says otherwise;
The revised reordered the endpoint suggests otherwise;
And even the current market cap, despite well undervalued, says otherwise.
GL.
Not correct. Below are primary and secondary endpoints according to Source: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB
Please pay attention to the third secondary endpoint (PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221), and the fourth secondary objective (OS, is overall survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.) these are the original primary and secondary endpoints!
"E.5 End points
E.5.1 Primary end point(s)
The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.
E.5.1.1 Timepoint(s) of evaluation of this end point
October 2020
E.5.2 Secondary end point(s)
The first secondary endpoint is overall survival (OS) compared between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in patients with recurrent GBM.
The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The third secondary endpoint, PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The fourth secondary objective, OS, is overall survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.
The fifth secondary objective is tumor response compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221."
The point is if topline data or unblinded data is known, are the parties in the know have the obligation to stop compassionate use (UK special program) in UK or anywhere it had been available before the know, if the data were bad or in other words, the data showed either not safe or not effective or both.
Although I have well past that psychological and scientific-based threshold, and just been wondering how success the data will be when it is revealed, there are always somebodies who would bring it about regardless the reasons behind.
In today's WS environment, almost all dead pigs (those stocks with prices stagnated for years) see their prices flying high regardless of fundamentals, we are siting in the narrow range of $1.5-$1.7, which makes me believe there have been indeed a great number of naked shorted shares still trapped.
And yes those few usual posters who claim having no shares/positions in NWBO but post 24/7 for years still glue in this board, repeating FUDs in hourly basis says yes they are trapped.
As Linda's friends, ie, those island boy financiers are diversifying their portfolios chasing any dead pigs they can find somewhere, we are patiently waiting. We will pass those boys who have no guts, vision and resources to buy in the open market to maintain a reasonable price, and enter a new investment world.
One of the dumbest things he has done, but he has had not other way out because the situation he faced at the time, is selling his vast holding of NWBO, if my memory can be relied upon, at around $0.19 a piece to Bigger C, etc.
The vultures always have meat in WS.
They are spoiled so no need to buy stocks in open market.
Was compelled to say a few words, maybe from drinking too much coffee this morning:
Avastin was approved by FDA in 2017 for rGBM patients for not improving OS but increased time to disease progression or death by about 2.7 months; [note it failed its primary endpoint of OS]
The current SOC for nGBM has not improved patient survivals for at least over a decade;
FDA approved Optune device for both n in 2015 and rGBM in 2011 has been controversial, but it doesn't prevent it from becoming a blockbuster treatment with market cap of about $19.5 billion today;
A great number of small developing stage biotech companies have seen their stock prices increased two to ten fold today from years of stalled prices in today's peculiar investment environment, despite many of these companies having no fundamental values at all but just stalled the price for a long time;
The 2018 JTM published DCVax-L data demonstrates both safety and efficacy of DCVax-L in treating nGBM. The following up data reveals an improved treatment trend;
The revised and reordered endpoints contained in the same revised SAP submitted to four RAs indicate the RAs have followed through with their understanding and updated guidance on the basis of the immunotherapy as a new class of cancer treatments which requires appropriate measurements for respective treatment efficiencies which are delayed but sustaining in nature;
From an educated guess and reasonable data analysis, the Phase 3 DCVax-L trial, datalocked as of 5 October, will be readily significant in meeting its primary endpoint, hence the investment in NWBO stock is no longer faced with a binary event.
And it can also be concluded from the above that it's highly likely the company has also been in negotiation with RAs for the approval of DCVax-L for rGBM besides the initial planned nGBM.
Since DCVax is a platform treatment for all solid tumors, if the price of DCVax-L for GMB indication is $10, then the price of NWBO by considering other indications shall readily reach multiple fold of the $10 as long as the concept of DCVax-L is approved.
Then, there will be the huge potential of DCVax-D coming into play.
The day of concept-of-approval unveiling DCVax-L trial data is quickly approaching!
I agree Swegen, but we have to take the first step before that.
The wall of $2, $3, $4, $5, $6, $7, $8, $9, $10, ... will fall as the platform is validated for the first indication of GBM.
We are so close to the major revelation. Besides what I said in my previous post, regarding our financiers, the so-called Linda's friendlies:
Despite having no guts and vision to buy shares in the open market so as to inject further confidence, hence better protect their own investment, they have mostly supported the grand scheme of Linda Powers of finally validating DCVax Platform for treating all solid tumors, by holding mostly their warrants/options not exercised.
But it seems these island boys and WS vultures have already de-risked enough, and gone into hibernation, by exercising and selling millions of warrants, selling shares against their warrants, etc.,
Plus one million verified shares increase in legal shorting scheme every two weeks, and disputed but trapped hundred of millions of naked short shares
that are some more signs we are really close to the serial of events we all have anticipated.
The dynamic shift is coming!
Reading your post I am actually relieved. Congratulations to you on your eventual figuring out how this management operates! Congratulations on your huge block on the ask!
This is exactly what I have anticipated what is going to happen as we are real close to huge revelation of the trial data in a unblinded way:
that retails would get enough of the bitter pill from waiting too long; new comers finally figured out how management is despising them, hence heading to exit;
that DI finally got enough, loosing temper telling some uneasy retails to shut up;
let alone the usual non-stop wolfpack nonsense! And the usual flip floppers is about to flip flop once again.
It must be close, really close!
Thank you Linda for holding your unswerving principles of not paying attention to retail nonsense, nuance, fuzziness, and instead focusing on the big picture, which in the end would benefit the true long much much more than that if the company is operated the usual way as some retails would like, for them making a dollar is a huge feast.
Pity those who still have not figured out how this management operates.
Too many signs pointing to success of not only a vaccine for GBM patients, but a paradigm shifting cancer immunotherapy platform for all solid tumors!
[be happy this company has been able to run as a private company so that Linda can be focused on the big picture!]
It's no longer a binary event. What it says to the price in the fine-tuned range of $ 1.5 ~ $1.7 or a market cap of around $1.3 billion:
Any shares below the price of $2 is a steal.
Just saying there are selling and there are buying. It's called market. Regardless what, either at price as high as $30 or as low as $0.14 there are always selling, and yes those sells are bought
So ladies and gentlemen, happy selling and buying as always
The difference is when fundamentals are confirmed for which many still fail to understand ever since the revised, reordered endpoints were revealed, the so-called binary event has long gone;
We are sensing now how successful the trial will be when TLD/detail data analyses are announced;
It has been a steady rise, despite in a slow pace, and this patter will soon be broken
It will be a rocket launch from the launch pad of $1.8 or $2
I am a buyer!
An advise from an animal science Full Professor, hope you have done well with your own money according to what you believe
My plain opinion is buy as many as you can afford at a price below $2
bye bye
Good luck to those who want to sell or threaten to sell
Good luck to those who bash hoping to get a position at a price as low as possible
Good luck to longs who have held for years, either adding more or holding steady
Karma to those who have ulterior agenda and bash day in and out 24/7 for years without having a position, long or short
In particular good luck to patients who are about to have an effective and extremely safe treatment, and for some a cure, of DCVax-L, with unprecedentedly solid, rich and long-term data in support
We are in a quiet period, a preparation for an explosive rise from a solid support of around $1.5 to $6 and beyond in in an instant any day now.
Yes any day, maybe 19 Feb, maybe today, and maybe 1 March
What the Fxx difference I see no
Thanks. If our financiers (the island boy club, the Bigger C, the thermo, and the like) can do just once a deal like this
Ocugen's stock triples on massive volume after institutional investors buy stock at a 27% premium
Published: Feb. 8, 2021 at 1:05 p.m. ET
By Tomi Kilgore
https://www.marketwatch.com/story/ocugens-stock-triples-on-massive-volume-after-institutional-investors-buy-stock-at-a-27-premium-2021-02-08
The market will say goodbye to $2 forever. No say they do it right now but the next deal if ever happens.
But they are all vulture in nature and lack of vision as I said repeatedly before so not really practical
While I agree with all what you said in your post, I do think confidence should be better injected through
Reading, studying and analyzing what we have learned about the current DCVax-L phase 3 trial for GBM patients, ie, the blinded, blended data published on
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
and subsequent uptrending updates by Drs LL, Bosch;
the history, status and outcomes of the current standard of care, which indicates there has been almost no change in extending patients' survival both in terms of median or long term survival;
All previous phase 3 trials for GBM, and their respective results, the reasons why they all failed; and
Though despised by the majority of oncologists taking care of their GBM patients for its unclear MOA, difficult to use and added burden for already great hardship of their patients, the FDA approved Optune device has panned out quite well, illustrating the huge unmet demand. And if NWBIO updated its long-term survival data, Novocure would mysteriously come out with some cherry-picking if not outright faked data trying to have a match. All in all, if DCVax-L is approved its market cap shall double, triple the Novocure's which is currently at $19 billion.
It's pretty much certain DCVax-L trial will be significant in meeting its primary endpoint.
WE are siting at a price range of $1.5 ~ $1.7 for quite a time for a market cap of about $1.3 billion.
Some long term holders are trimming fat becoming lighter if not completely out of the game, new comers are mostly bashing (of course they want to initiate a position at a price as low as possible), and from time to time a tiny fraction of warrants gets dumped onto market. We are at a point now even nobody bothers to report their communications with DI or Les. The darkness seems to be upon us. How this situation can last.
I added about 100,000 shares in the last two weeks bringing my average up a bit
Good luck to you and all long
Too much nonsense as usual so I want to cut my post to the bone talking purely about buying, holding or selling nwbo for profit.
The status: today is more than 4 months after DL pr
For most small biotech companies they would have already pr tld, and yet we have not seen the tld pr yet because the company suggested they would announce tld and a publication in a closed by fashion.
A publication of detail data analysis according to Highwayman's link takes a year in average. However, NWBIO is not any way of that average company, and there are also examples of companies which take only a couple or a few months after DL for a publication for detail analysis.
For NWBIO
1) it's suggested NWBIO would release tld and publication almost simultaneously, unlike any average company which usually releases tld within two months of its DL pr, which takes the pressure off from publication (NWBIO is pressured for a quick publication from various fronts without announcing tld as soon as possible from DL pr);
2) NWBIO needs to raise funds for operations, and it cannot do that a) withholding tld/knowledge of trial results; and b) because it has run out of authorized shares.
As a result, NWBIO must pr tld at least in the near future if publication is still far away due purely to its financial needs. As a matter of fact, since it's already four months after DL pr, it's highly likely the publication may be about ready on any day ahead. Besides, the annual shareholder meeting is fast approaching, if prior years' experiences is a guide, we may be receiving notice on any day within this month. It's highly unlikely NWBIO would not reveal tld on or before the shareholder meeting.
Bottomline, from all we have known, it's quite probable DCVax-l P3 trial for GBM is significant in meeting its primary endpoint, and it's also quite probable it also meets some of its secondary endpoints. If DCVax-l is approved, it's very practical NWBIO would quickly achieve dominant market success/shares. A share price of $10 is readily achievable shortly after successful tld pr...
Conclusion:
No matter how patient you are or will be, the trial is most probably successful in meeting its major endpoints for nGBM, and it's an educated/studied speculation NWBIO may also seek approval of rGBM, which may explain at least in part for the existing long quiet period.
I don't know about you. Definitely as I have said several times in the past few months, I am a buyer, ie, net net my shares have steadily increased, bringing my average price steadily up.
For that I completely agree. That is why sometimes I rant, particularly on those island boy financiers, or the like such as Bigger C.
They lack of strong conviction, and are vulture in nature.
They are too passive no guts and too selfish and lack of vision
So no buy from open market.
But still it's totally out of our control, and at least I know what I am going to do
Not help man it's out of your control!
If they don't have the conviction and you have, let them sell and buy as much as you can afford at any opportunist time if any.
That's what I have done despite occasional rant.
In almost all the cases, old timers are thinner if not completely out of the game, new bloods come in in trough despite not yet so far, they will, as patience wears thin and dry, DI cannot catch up with new angry emails and phones
That's when it's time, not timed of course just my humble observation of more than two decades small biotech investment experience.
No complain today I am a buyer.
You have given very precise and succinct answers to the questions asked by the previous poster with a lot of critically important information. Thermo thank you.
I don't want to comment on each of your answer, but this particularly one, "She then compared the treatment arms in prior failed trials to the pooled ECD from the 5 trials. These trials failed when compared to internal SOC. These trials would also fail when compared to the ECD."
This should shut the fxxk months off of all the naked short wolfpack posters and elements present or not present in this board.
BTW, our treatment when compared to the internal SOC of the same pooled ECD from the 5 trials IMHO will be significant.
It suggests the treatment effect of DCVAx-L trial in GBM will be real, undeniable.
Can thermo's post be sticked?
You are welcome. I appreciate very much your support to the cause of what NWBIO has been in pursuit for over a decade!
NWBIO wins, we all win, let alone long suffering patients.
I think it's pathetic for you, a hedge fund manager/owner to promote other stock you have involved in financing in nwbo board. That says a lot about you. Of course other big names of nwbo financiers like bigger who had pounced when opportunity existed and never/almost never ever buy nwbo in the open market, and who know he might in effect have sold against his warrants.
You guys' shaky long thesis on nwbo is equally pathetic, or we would have seen some open market buy activities, or SEC reports, despite operated off the islands or something to that effect. By doing so [buying in the open market], you would protect your positions with appreciated share price and more market visibility
I have been in and out of otlk over the years, profitable but never ever has had the conviction I do in nwbo, a paradigm shifting cancer treatment platform.
Nothing wrong with what you are doing though, just cannot help.
Gap up today still in play!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161289177
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161292257
GAP UP TOMORROW
We shall see.
Please note the naked shorting scheme has been in design and practice against vulnerable, financially-distressed small companies, particularly small developing stage biotech companies facing a binary event of to live or to die
It's proven lucrative for naked shorting hedge funds for obvious reason: most such companies have gone under statistically and historically. So you can randomly pick any one of such company and the chance is very high that the company probably is under attacked by naked shorting.
The most significant characteristic of naked shorting is its stealthiness, secrecy, intended to practice without notice, and it's in a way sanctioned by SEC in the name of weeding out weeds (targeted small companies) for healthy growth for big multinationals, hereby maintaining market stability while protecting more victims (retail investors by discouraging investing in small companies).
They (naked shorting practice) will come and gone with huge profit untaxted for naked shorting hedge funds, only changes are the names of the companies they pounce upon, which will later disappear as well from their books buried in newly made billions
For this reason, the naked shorting scheme is rarely designed and practiced against big corporations, because it's almost impossible to maintain the stealthiness and secrecy needed for such lucrative practice if big corporations are naked shorted against.
As I said, we shall see
[In the case of NWBO, despite their decision to naked shorting of the naked shorting wolfpack, now they must have realized they will be wiped out if they still hold their naked shorting position all the way to TLD. Again we shall see]
[And I do agree with most people that the naked shorting hedges will in most times get news earlier than retail investors, which will be a sign to watch as well]
Those are mostly legally shorted (borrowed, sold), despite strong indication of naked shorting, i.e., 138% shorted shares for GME.
In NWBO's case, the legally shorted shares are peanut, or in other words, normal or healthy, but the speculation/suspicious is the shares shorted are mostly naked shorted shares which cannot be proven or easily looked up from any reporting.
Because of the collapse of share price from $12.5 all the way down to $0.14, the logic thinking is those naked shorted shares years ago must have been closed (bought back), particularly after rounds after rounds of diluted financing.
Nonetheless, judged by how this stock has been trading since then (shortly after the partial halt of new patient screening back in 2015), there has been no sign of completely closing out of naked shorted shares, and there is strong indication of new naked shorted shares at much lower price.
Most longs, myself included have bought our most shares at almost lowest price range from $0.14 ~ $0.20 (my estimation is that those shares could be at least in several hundreds of millions), while there had been no sign of significant share price appreciation despite hundred of million share purchases, which is one more suggestion of the existence of naked shorting, even at that low share price range.
Yes, nobody can provide solid evidence for naked short wolfpack with hundred of million naked shorted shares, except the company once indicated there were a large number of shares unaccounted.
Personally, I believe there are a large number of naked shorted shares which have not yet fully covered.
This actually is a good relief for me in today's environment. After all, all forces against NWBO are doomed to fail, which is what we all should be confident from all we have known:
Blinded, blended data, historical norm, failed trial data
Anytime now the unblinded data could be known, regardless of whatever the form of releasing
Revised, reordered endpoints, most probably the primary endpoint is significant
I will buy any existing shares below $2 as much as I can
[regarding naked short practice, I had a post yesterday explaining one possibility: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161207158]
expect a later day rally, if not earlier! It's a way of stealing built on auditor change, which normally views as negative.
But the fact will soon set in that is the change is at least nothing burger or as I view it a positive.
And the naked short wolfpack will lose huge if they are dumb enough to wait or slow buying back
Nobody knows when announcement will come!
GLTYL
Please pay particular attention to jane and cdel. Both are "true" market makers, aka market manipulators in recent month.
It seems both were forced to reverse course, and need to load up. But they could also pounce back anytime.
Anything below $2 is a steal! We ought to bury these shits forever.
Only way to win for big boys is to steal, until we are united...
My takeaway of changing auditor from Marcum to Cherry Bekaert LLP is hugely positive. My speculation is that
1) The company's repeatedly delays of financial filing have had something to do with Marcum which might be deliberate in the most recent filing delay, and Linda finally got fired of and decided to move on with other firm. It seemed the change was intentionally driven by Marcum making Linda to say enough... and
2) Now Marcum is free of taking a position buying NWBO.
Shorts are bleeding everywhere noways. NWBO's shorts have taken notice. With average IQ, the wolfpack naked short knows what they have to do.
TLD or data release in whatever form will be announced no matter what, and each passing day is a day close to the revelation.
There are too many positive fronts ongoing, and please hold your shares or even add more if you can
Any price below $2 is a steal!
Shorts have been losing in the past year, and is losing big betting Biden administration will tighten, interest will increase...
Nowadays, there is no difference between Dem and Republic governments. Both cater to the instant demand of the current generations, ignoring the future generation, creating all kinds of bubbles.
Don't care about the future has become the trend principle of the free world.
Anyhow, shorts are domed to lose big holding shorted NWBO shares, it's just the time, and they will lose bigger under Biden's first year, a year to appease to the popular demand of the people, a year of printing even more money than Donald ever had
Somebody thinks naked short wolfpack has to follow the laws and regulations simply because all trading is now digitized.
Never heard or unable to understand the dark pool of underground world, and yes all transactions are recorded digitally?
Never heard or unable to understand market makers can legally carry balance each and every reporting period, and the balance is a mix bag of numerous different stocks, derivatives, etc.,[it's allowed by the law to "create shares" to provide liquidity, but the law can be readily taken advantage of by its own setting] for which SEC little heads will find either too complex to understand or too huge a burden to verify, or at least watch some porn will be easier to kill time.
That legal carried balances change with time in terms of stocks and derivatives of their carrying dynamically.
At the choosing of MMs or their clients driven by greediness and savvy or dumb decision, buried in the darkpool/legally carried balance week after week, quarter after quarter, and year after year are stocks naked shorted
For some stocks trading in OTC particularly, and stocks of small developing stage biotechs, the odds are high that the stocks will disappear, and the name of the stocks would disappear from the darkpool/carried balance, and new stock names would be added in the never verified, ever-changing, mixed-bag dynamic flowing balances. And in case SEC staff tired of watching porn and decided to get to the bottom of one MM's illegal practice, before SEC can sniff around, the balance swapped with the balance of other MM, in part or completely, though never heard SEC has ever gone that deep.
It's an illegal but profitable practice "sanctioned by SEC" and it will never change.
The perpetrators are laughing to the bank pissing SEC and vast numbers of investors in most cases, that makes it never-get-punished, SEC-sanctioned, profitable practice....
But this is what I know they may laugh to the banks for other stocks, they will pay the price for naked shorting NWBO.
But number two, I do think the naked short wolfpack by now must understand their decision was wrong, and they are trying to find the right time to clear those naked short shares, which we will see when that is going to happen. If they are smart enough, better before TLD or the announcement re trial data in whatever form.
[my personal guess is that the naked short wolfpack has unloaded some naked short shares already, it may not be of a significant number. And I do believe the pack understands it has to unload all their positions because even them understand DCVax-L trial will be a success, maybe they are waiting to see as we long do how successful the trial will be.]
I realized it's hypothetical, but defending the company in this way, despite hypothetical, is absurd.
Don't think Linda is anyone close to a crook. As a matter of fact, my investment decision, unlike many others who dislike the fact that NWBIO has been run by two successful high-profile former lawyers, was initially made exactly because of that very fact, which suggested to me NWBIO might be run in a way of constant walking on the borderlines [timeline delayed, delayed, and delayed, kicking the can, carrot dangling, and you named it, which are all part of my understanding], but the outcome pursued thereafter would not be anything close to an instant rich/results for they are already rich, because the outcome has to be legendary if science is solid and continued to be proven solid.
Remember go big or go home! Only very successful persons like Linda and Les have such luxury to run a company "like playing a toy," not for instant results, not succumb to any unnecessary unwanted external pressure.
Only thing I have ever complained is Linda's greediness of awarding herself too many options/warrants at too low target prices. Even today, I still don't think Linda had no ways to cause a much higher historic lowest price, partly because she could make all up by rewarding herself more options/warrants at lower price, but for us retail investors we have had to put much much more hard-earned money to average down to make up, which is suck to say the least, although it's a trajectory I determined to follow.
After both UK and Germany were somewhat onboard which further validated the science, I finally decided to go big on my NWBO investment. Occasionally selling some, but always bought back and more. Now I (my family fund) is too deep in NWBO which has become my largest single stock holding ever, along with just a few other stocks in much much less significance.
IMHO, I have the trust that Linda would have let the public know if the trial's primary endpoint were a miss. For me that's the very basic of my belief; defending the company for whatever reason if the trial were a miss in the primary endpoint without a public announcement shows lack of trust in the company and absurd blindness.
Of course as I said repeatedly, it is a moot point to further discuss this hypothetical situation, because it's highly probably the trial is significant in meeting its primary endpoint.
Good luck to you!
welcome onboard again my friend, agree on all you said except that I do think investors can have a sigh of relief we have not had negative news yet wrt the trial since data was locked on 5 Otc.
All the best and good luck!
Some things come to my mind in this minute: [this post is not intended to reply to fox, sorry]
nwbo trial registry has not been updated since Oct 2016, even after the partial halt for new patient screen was lifted by FDA in early 2017
if lifting of a halt has been ignored why this revised endpoints?
Personally I don't want to have anything be documented and later find it may hinder flexibility in dealing with FDA as FDA is such a rigid beast
All signs points to positive outcome of the trial, hereby the company, its investors, and most importantly for GBM patients -- no distraction from the company to launch new trials, or buying a tiny biotech to expand pipelines,
No major shareholders and insiders have cashed in, leaving huge mountain high, ocean deep derivatives and shares intact....
All in all not much of a fanfare for anything [expanding patents, manufacturing progress,...], but deafening quietness!
utter nonsense.
First most investors don't think there is a tiny chance of trial failure in primary endpoint
Second if it were a failure measured by primary endpoint, the trial failed by its own definition according to its own SAP. It failed PERIOD
No excuse to withhold the data to the public because of further analyses, or confirmation analyses, or data mining to find other silver lining
Even afterwards the fate of the trial now deemed failure may reverse course (yes there is chance there), it doesn't change the trial failed initially according to its SAP
Thus the company must release the news to the general public even if ultimately the trial would be saved and regained chance of approval.
It's two different things. First you must disclose trial failed in terms of its primary endpoint not meeting predefined metric, and later you also must disclose the trial still has chance of showing both safety and efficacy derived not from its primary endpoint meeting its predefined goal, but from other supporting and persuasive data.
There will be no leeway; otherwise it will become the Old West.
Bottomline: this is a moot point, because the trial is highly likely to meet its primary endpoint in a statistically significant way, hereby the trial will be a success!
will be approved in UK first within a foreseeable future, followed by EU and the US.
Linda has been focused on the ultimate commercial success of DCVax platform, not everyday's price ups and downs and some retail investors' mood swinging. By doing so she can avoid trivial and potential disruption such as threats of potential lawsuits (in American you can suit anybody with anything with any negative clue real or not real!) Yes she has the fiduciary duty for her shareholders, but not for day to day share price swing!
She wants to give true shareholders a price of, for example $5 as starter when a major news is released and save the long the struggles to consider selling some of their shares when the price experiences ups and downs, for example in the range of $1 to $3.
Not necessary exactly would happen like the above, but I do like the scenario, and I hope it goes exactly that way.
It's a steal to have a share price below $2 now.
It's my last post for today. GL.